Ajanta Pharma Q3 FY26: revenue up 20%, PAT up 18%

Revenue Growth 20pctEmphasis Of MatterResults View source PDF Explain this filing

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹2691.00

prior close

₹2788.20

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.0%+2.8% vs market

Pharmaceuticals peers, median of 157sector+0.9%+1.9% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.2

15m

-0.6

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9+0.0+2.8+0.9+1.9

Next day

+3.3-1.1+4.4+0.4+3.0

+7.0+1.8+5.2+2.4+4.6

+4.9+2.4+2.5+2.9+2.1

+4.6+2.1+2.5+2.2+2.5

+5.2+2.1+3.2+2.1+3.2

+7.1+4.1+3.0+4.3+2.8

15d

+9.1+2.0+7.0+1.2+7.9

+10.4-0.0+10.4-0.6+11.0

+3.5-9.6+13.1-10.4+13.9

+5.2+2.4+2.8+3.2+2.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ajanta Pharma reported strong Q3 FY26 results. Consolidated revenue rose 20 percent to Rs 1,375 cr; PAT grew 18 percent to Rs 274 cr; EBITDA up 19 percent to Rs 382 cr with margin at 28 percent. For 9M FY26, revenue grew 16 percent to Rs 4,031 cr and PAT 14 percent to Rs 789 cr. US generics surged 52 percent in Q3, India branded generics up 19 percent. Auditor B S R and Co gave unmodified opinion but flagged August 2025 Income Tax search operations.

Likely market impact

Strong quarter with broad-based growth across India and US. Income Tax search from August 2025 remains an unresolved overhang.